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Abstract
Objective: Routine extrahepatic bile duct (EBD) resection in non-jaundiced patients with gallbladder
cancer (GBC) is controversial. The aim of this study was to retrospectively analyse patterns of recurrence
in patients who underwent resection of GBC without routine EBD resection.
Methods: This analysis referred to 58 patients who had undergone explorative laparotomy for GBC
during 2000–2012 at a single, tertiary referral centre. Overall survival, time to recurrence, and patterns of
recurrence were assessed in patients who underwent conventional negative-margin (R0) resection
without routine EBD resection.
Results: Of 58 patients submitted to explorative laparotomy for GBC, 26 (45%) patients underwent R0
resection without EBD resection (tumour stage T1b in five patients, T2 in 17, T3 in three, and T4 in one).
The 3-year survival rate among these patients was 78% at a median follow-up of 33 months (range:
13–127 months). Seven patients developed recurrent disease at a median of 9 months (range: 2–25
months) after resection. No patients developed isolated recurrent disease at the EBD.
Conclusions: Of 26 patients resected for GBC, none developed isolated recurrent disease at the EBD
after conventional resection of GBC without EBD resection. This finding suggests that routine EBD
resection is of no additional value.
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Introduction
The surgical treatment of gallbladder cancer (GBC) is predomi-
nantly guided by the extent of tumour invasion.1,2 A potentially
curative resection requires tumour-free margins and regional
lymphadenectomy in patients with disease of stage T1b or
higher.3,4 The aim of regional lymphadenectomy is to improve
the curative potential of resection5,6 and to assess the stage of the
tumour for prognostication.7,8 Resection of the extrahepatic bile
duct (EBD), however, is controversial in GBC patients, whether
or not they show involvement of the EBD. For patients with EBD
involvement, there is disagreement on the benefit of surgical
resection.9,10 The present paper discusses the value of routine
EBD resection in patients who have no obstructive jaundice, no
macroscopic involvement of the EBD, and a negative cystic duct
margin.
Routine EBD resection has been performed for GBC with
varying frequency in many centres.1,10–14 The rationale for this
approach is that cancer cells may have spread not only to the large
lymph vessels in the subserosal layer around the EBD, which are
resected during conventional lymphadenectomy, but also to small
lymph vessels in the submucosal layer of the EBD.10,13,15 However,
no studies have been able to show improved survival with routine
EBD resection.12,16 In addition, it has been demonstrated that EBD
resection does not increase the completeness of lymphadenectomy
of the hepatoduodenal ligament.1 Hence, although EBD resection
is associated with increased morbidity and mortality, there is no
evidence that routine EBD resection is of any oncological
benefit.1,17
In the Academic Medical Centre (AMC) in Amsterdam, GBC
resection without EBD resection has been the standard approach
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in patients who have no signs of obstructive jaundice, no macro-
scopic involvement of the EBD and a negative cystic duct margin.
It is uncertain whether this policy’s potential leaving of cancer
cells in the submucosal layers of the EBD negatively impacts sur-
vival. As most patients develop distant disease as the initial pattern
of recurrence after GBC resection,18 the present study was based
on the hypothesis that GBC patients are unlikely to develop an
isolated regional recurrence at the EBD after GBC resection
without routine EBD resection.
The aim of this study was to assess patterns of recurrence in
patients who underwent conventional resection of GBC without
routine EBD resection.
Materials and methods
Patients
Consecutive patients who underwent explorative laparotomy for
GBC at the study institution tertiary care referral centre between
January 2000 and April 2012 were identified by reviewing pathol-
ogy registries and medical billing records. Inclusion criteria
required patients to have undergone negative-margin (R0) resec-
tion of GBC (i.e. adenocarcinoma of hepatobiliary origin or pap-
illary malignancy, originating at the gallbladder or at the cystic
duct) and laparotomy at the AMCAmsterdam, either because of a
primary suspicion of GBC or subsequent to a previous non-
curative cholecystectomy at a referring centre (i.e. incidental GBC
found at pathology review). All patients with a positive-margin
resection (R1 or R2) or no resection were excluded, as were
patients with an indication for EBD resection. Indications for
EBD resection were: preoperative obstructive jaundice; macro-
scopic involvement of the EBD, and a positive cystic duct margin.
Clinical and pathological data were retrospectively collected from
the medical records.
Surgical resection
Resection of the tumour in patients who presented with a primary
suspicion of GBC consisted of a locoregional lymphadenectomy
and en bloc cholecystectomy with a hepatic resection. Definitive
resections were performed in patients who had undergone a pre-
vious non-curative cholecystectomy at a referring centre, consist-
ing of locoregional lymphadenectomy for GBC of stage pT1b or
higher, and additional hepatic resection for disease of stage pT2 or
higher. Hepatic resections consisted of the excision of a wide
wedge of segments IVb and V, or a right hemi-hepatectomy
extended to segment IVb depending on the liver involvement of
the tumour. Indications for right hemi-hepatectomy were: hepatic
invasion not radically resected with segment IVb/V wedge resec-
tion, and tumour involving the right posterior portal pedicle.
Infiltration into other adjacent organs required the resection of
involved structures, most commonly parts of the colon or duo-
denum.The EBDwas preserved in all patients in this study cohort.
Standard lymphadenectomy included the harvesting of all
locoregional lymph nodes [i.e. the N1 lymph nodes according
to the seventh edition of the tumour–node–metastasis (TNM)
classification],4 and excision of all lymphatic tissue in the
hepatoduodenal ligament, resulting in the complete skeletoni-
zation of the portal vein up to its bifurcation and the proper
hepatic artery, including the left and right hepatic arteries. Lymph
nodes beyond the hepatoduodenal ligament (i.e. along the
common hepatic artery) were not included in the standard
lymphadenectomy.
Follow-up
Overall survival, disease-free survival and patterns of recurrence
were analysed. Patterns of recurrence were determined from com-
puted tomography (CT) imaging studies conducted 3 months
postoperatively and when indicated by clinical signs of recurrence
(e.g. recurrent jaundice, abdominal complaints or fatigue) at
further clinical follow-up. For patients who had no clinical
follow-up until 1 April 2012, disease status was assessed by con-
tacting the primary care physicians who had monitored clinical
signs of recurrence and had referred patients for CT imaging if
indicated. If applicable, details on tumour recurrence were
obtained from the regional hospitals at which tumour recurrence
had been diagnosed. Tumour markers were not monitored in a
standard way. The diagnosis of recurrent disease was confirmed by
histological analysis if possible. Since 2010, patients with recurrent
disease have been considered for systemic treatment with cisplatin
and gemcitabine.19 ‘Patterns of recurrence’ were classified as
local (liver resection margin, EBD or liver hilum), or distant
(intrahepatic but away from the resection margin, retroperitoneal
lymph nodes, peritoneum and abdominal wall).18 ‘Time to recur-
rence’ was defined as the time between definitive resection and the
first suspicious radiological finding of recurrent disease. ‘Overall
survival’ was defined as the time between definitive treatment and
the date of death, which was retrieved from the Dutch municipal
population register.
Statistical analysis
Continuous data are presented as the median (range). Independ-
ent variables were dichotomized. Associations with the depend-
ent variable for tumour recurrence were analysed using Fisher’s
exact test. Kaplan–Meier estimates were used in analyses of
overall survival and disease-free survival, and differences in
overall survival were analysed using the log-rank (Mantel–Cox)
test. P-values of < 0.05 were considered to indicate statistical
significance.
Results
A total of 58 patients who had undergone explorative laparotomy
with curative intent for GBC were identified at the AMC Amster-
dam. Twenty patients did not undergo resection at explorative
laparotomy because of extensive disease or distant metastases.
Thirty-eight patients underwent a resection (resection rate: 66%).
Patients who required an EBD resection (for macroscopic EBD
involvement in three patients and for a positive cystic duct margin
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in three patients), and patients in whom an R1 or R2 resection was
achieved (n = 6) were excluded. An R0 resection without EBD
resection was achieved in 26 patients; these patients represent the
study group (Fig. 1). Demographics, treatment and pathology
results are presented in Table 1.
A previous laparoscopic cholecystectomy (i.e. an incidental
finding of GBC) had been performed in 12 patients, who had been
referred for definitive surgery. In these 12 patients, the depth of
tumour infiltration was pT1b in three patients, in whom only
lymphadenectomy was undertaken at explorative laparotomy. The
remaining nine of the 12 patients had pT2 disease and underwent
segment IV/V resection in combination with lymphadenectomy
at explorative laparotomy. The median time between cholecystec-
tomy and definitive surgery was 8 weeks (range: 3–17 weeks).
Survival
Ten of the 26 study patients had died at last follow-up; of these 10
patients, three showed no signs of GBC recurrence at the time of
death. The median length of follow-up of the 16 patients who
remained alive at the last follow-up was 33 months (range: 13–127
months). The rate of 3-year overall survival was 78%; median
survival was not reached (Fig. 2). Lymph node status was signifi-
cantly associated with overall survival (P = 0.04), whereas depth of
tumour invasion was not.
Initial disease recurrence
Univariate analysis found no statistically significant associations
between the depth of tumour invasion or lymph node status, and
tumour recurrence (Table 2). The anatomical locations of initial
tumour recurrences are presented in Table 3. Four patients devel-
oped recurrence at a local site, involving the liver resection margin
in two patients, the liver hilum in one patient, and the EBD in one
patient. Local recurrences in these four patients were confirmed
histologically. The two patients with local tumour recurrence at
the liver hilum or the EBD had synchronous recurrence at distant
sites: one patient had synchronous peritoneal metastases, and one
patient had synchronous abdominal wall and greater omentum
metastases, which may have resulted from tumour spill at a pre-
vious laparoscopic cholecystectomy. The median time to initial
recurrence was 9 months (range: 2–25 months). Nineteen patients
had no evidence of tumour recurrence at the time of death or at
the most recent follow-up.
Discussion
In this cohort of 58 patients undergoing explorative laparotomy
for GBC, no patients underwent routine resection of the EBD. Of
26 patients who underwent R0 resection of GBC without EBD
resection, four patients developed local recurrence. Two patients
had local recurrence in the region of the EBD (i.e. at the liver
hilum or in the EBD), but both of these patients also presented
with synchronous distant metastases. No patient developed an
isolated local recurrence in the region of the EBD.
A retrospective nationwide study conducted in Japan compared
EBD preservation and EBD resection in 399 and 194 patients,
respectively.12 This study included only patients without macro-
scopic involvement of the EBD. No difference in overall survival
was found for any subgroup of patients grouped by T-stage or
N-stage. Two Western studies have also compared patients in
whom the EBD had been preserved or resected, and revealed no
R0 resection
(n = 32)
R1/2 resection
(n = 6)
Explorative laparotomy
for GBC (n = 58)
EBD resected
for EBD involvement
(n = 6)
EBD preserved
No EBD involvement
(n = 26)
No resection
(n = 20)
Figure 1 Flowchart showing surgical outcomes in patients undergo-
ing explorative laparotomy for gallbladder cancer (GBC). In 26
patients, a negative-margin (R0) resection was achieved with pres-
ervation of the extrahepatic bile duct (EBD)
Table 1 Demographics, treatment and pathology of patients under-
going negative-margin (R0) resection of gallbladder cancer without
resection of the extrahepatic bile duct (n = 26)
Characteristics Value
Sex, female, n 19
Age, years, median (range) 64 (48–82)
Preoperative jaundice, n 0
Previous cholecystectomy, n 12
Tumour stage, n
T1b 5
T2 17
T3 3
T4 1
Node stage, n
N0 18
N1 6
Nx 2
Hepatic resection, n
Cholecystectomy 5
Segment IV/V wedge 19
Right hemi-hepatectomy 2
Additional resections, n
Partial duodenum 1
Regional lymphadenectomy, n 26
Lymph nodes harvested, median (range) 3 (0–11)
Nx, lymph node status not available in pathology report.
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differences in overall survival. However, in these studies > 50% of
EBD resections weremandated by clinical involvement of the EBD
representing more extensive disease.1,20 The present study shows
that of 26 GBC patients who underwent an R0 resection without
routine EBD resection, not a single patient presented with an
isolated recurrence in the region of the EBD. These results support
the omission of routine EBD resection in the treatment of patients
with GBC.
By contrast with these results, several studies have investigated
histological tumour spread to the EBD in the resection specimen
of non-jaundiced patients. These studies found tumour cells in
the EBD in 19 of 44 patients with T2/3 GBC and in 16 of 42
patients with T3/4 GBC.10,13 A third study found tumour cells in
the submucosal lymph vessels of the EBD in three of 15 patients
after resection of T2 GBC.15 Another advantage of routine EBD
resection is that it may enhance locoregional lymphadenectomy,
but no differences in lymph node count were found between
patients who had undergone EBD resection and those who had
not.1 To summarize, omitting EBD resection potentially leaves
behind micro-metastases in submucosal lymphatic tissue in the
EBD; however, it is unlikely that routine EBD resection will
improve overall survival in patients undergoing R0 resection of
GBC without macroscopic involvement of the EBD.
Although the benefit of routine EBD resection is uncertain, it
is associated with increased morbidity and mortality in both
Western and Asian series. In a series of 104 patients who had
undergone resection for GBC, 33% of patients in whom the EBD
had been resected developed a complication that required a
re-intervention, whereas only 13% of patients in whom the EBD
had been preserved did so.1 Another recent study showed that the
rate of postoperative bile leakage increased from 3% to 14% when
liver resections for various indications were combined with EBD
resection.17
The observation in this study that most patients who present
with recurrence after radical resection of GBC are diagnosed with
distant metastases is consistent with the findings of previous
studies.18 This finding reflects the aggressive biology of GBC and
the associated poor survival, especially in patients with positive
lymph nodes. Micro-metastases remain undetectable by preop-
erative imaging and during surgery, suggesting a role for adjuvant
systemic treatment. However, a recent meta-analysis based on six
retrospective studies involving 4450 patients with GBC found no
significant difference in 5-year survival between patients who did
and did not receive adjuvant treatment.21 Systemic treatment with
cisplatin plus gemcitabine is currently established as palliative
treatment,19 but benefits established in a palliative setting do not
always translate to an adjuvant setting. Randomized trials are
needed to further evaluate adjuvant therapies in GBC.
This study is limited by its retrospective study design and the
lack of a control group of patients submitted to routine EBD
resection. Some patients in the study group had undergone a
previous laparoscopic cholecystectomy. This difference in treat-
ment introduces heterogeneity into the relatively small group
of patients. In addition, the median time between laparoscopic
(a) (b)
Figure 2 Survival curves for patients who underwent negative-margin (R0) resection of gallbladder cancer with preservation of the extra-
hepatic bile duct. No patients were lost to follow-up. (a) Overall survival curve. The median survival was not reached. The estimated 3-year
survival rate was 78%. (b) Survival curves according to lymph node status. Patients with N1 (n = 6) and Nx (n = 2) disease were pooled.
Patients with N0 disease had significantly better survival than patients with N1/Nx disease (P = 0.04). No significant association emerged
between survival and depth of tumour invasion. Nx, lymph node status not available in pathology report
Table 2 Univariate analysis of factors associated with recurrence
Factor No recurrence
(n = 19), n
Recurrence
(n = 7), n
P-value
Depth of tumour invasion 0.28a
T1b 5 0
T2 12 5
T3 2 1
T4 0 1
Lymph node status 0.15a
N0 15 3
N1 4 2
Nx 0 2
aAnalyses (Fisher's exact tests) were based on comparisons between
patients with stage T1b versus T2/3/4 disease and N0 versus N1/Nx
disease, respectively.
Nx, lymph node status not available in pathology report.
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cholecystectomy and definitive surgery may have exposed patients
to occult tumour progression, although only one of 12 patients
with a previous laparoscopic cholecystectomy developed tumour
recurrence during the study period. Furthermore, the study is
limited by its small sample size and short follow-up. As well as
imposing limitations on the general conclusion, the small sample
size of patients with this rare disease hampered the detection of
factors prognostic of tumour recurrence other than lymph node
status. However, this study is the first to explore the value of
routine EBD resection by analysing initial patterns of recurrence.
In conclusion, this study shows that none of 26 GBC patients
who underwent an R0 resection without routine EBD resection
developed isolated recurrence in the region of the EBD. This
finding suggests there is no additional value to be derived by
performing routine resection of the EBD in patients who have no
involvement of the EBD and have a negative cystic duct margin.
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